Concert Pharmaceuticals, Inc.

Concert Pharmaceuticals Initiates Phase 2 Clinical Trial Evaluating CTP-499 for the Treatment of Diabetic Nephropathy

Concert Pharmaceuticals Initiates Phase 2 Clinical Trial Evaluating CTP-499 for the Treatment of Diabetic Nephropathy

March 5, 2012

LEXINGTON, Mass.--(BUSINESS WIRE)--Mar 5, 2012 - Concert Pharmaceuticals, Inc. today announced the initiation of dosing in a Phase 2 clinical trial evaluating CTP-499, an investigational drug for the treatment of diabetic nephropathy, the leading cause of chronic kidney disease (CKD) in the US.

Affinnova, Inc.

Innovation Software Produces Products Twice as Successful in the Marketplace, According to Affinnova Study

Innovation Software Produces Products Twice as Successful in the Marketplace, According to Affinnova Study

March 1, 2012

WALTHAM, Mass.--()--A recent study by Affinnova, Inc., the global leader in innovation software and services, quantified the boost that products identified through concept optimization technology can expect in market.

Concert Pharmaceuticals, Inc.

Avanir Pharmaceuticals and Concert Pharmaceuticals Announce License Agreement to Develop and Commercialize Deuterium-modified Dextromethorphan for Disorders of the Nervous System

Avanir Pharmaceuticals and Concert Pharmaceuticals Announce License Agreement to Develop and Commercialize Deuterium-modified Dextromethorphan for Disorders of the Nervous System

February 29, 2012

ALISO VIEJO, Calif. and LEXINGTON, Mass., Feb. 29, 2012 /PRNewswire/ -- Avanir Pharmaceuticals, Inc. (Nasdaq: AVNR) and Concert Pharmaceuticals, Inc.

Selventa

Selventa Announces a Research Agreement to Understand Mechanisms of Disease

Selventa Announces a Research Agreement to Understand Mechanisms of Disease

February 27, 2012

CAMBRIDGE, Mass., Feb 27, 2012 (BUSINESS WIRE) -- Selventa(TM), a personalized healthcare company focused on stratification of patients and development of predictive biomarker panels based on disease-driving mechanisms, today announced a research agreement in the area of immunological disease with Janssen Research & Development, LLC. The focus of this multi-year research agreement includes development of disease models using diverse biologic data to elaborate disease-relevant mechanisms and identify potential new drug discovery opportunities.

 

Permeon Biologics Inc.

Permeon(TM) Biologics Announces the Appointment of Katherine S. Bowdish, Ph.D., as President and Chief Scientific Officer

Permeon(TM) Biologics Announces the Appointment of Katherine S. Bowdish, Ph.D., as President and Chief Scientific Officer

February 23, 2012

CAMBRIDGE, Mass., Feb 23, 2012 (BUSINESS WIRE) -- Permeon(TM) Biologics, a biopharmaceutical company pioneering a novel class of intracellular protein biologics, today announced the appointment of Katherine S. Bowdish, Ph.D., as president and chief scientific officer. Dr. Bowdish also joins the Permeon board of directors. Previously, Dr. Bowdish was the co-founder, president and chief executive officer of Anaphore, a platform-based drug development company pioneering Atrimers(TM), a new class of trivalent protein pharmaceuticals.

Mascoma Corporation

Mascoma Announces FDA Favorable Review of Drop-In MGT™ Yeast Product

Mascoma Announces FDA Favorable Review of Drop-In MGT™ Yeast Product

February 22, 2012

Lebanon, New Hampshire – February 22, 2012 – Mascoma Corporation, a renewable fuels company, announced today that the U.S. Food and Drug Administration’s (FDA) Center for Veterinary Medicine has completed its scientific review and supports the use of the Mascoma Grain Technology, or MGT™, yeast product as a processing aid in the production of animal feed, which is a by-product of the corn ethanol conversion process.

Receptos, Inc.

Receptos Scientists Publish Determination of a High Resolution Sphingosine 1-Phosphate Receptor 1 Structure in Science

Receptos Scientists Publish Determination of a High Resolution Sphingosine 1-Phosphate Receptor 1 Structure in Science

February 16, 2012

SAN DIEGO, Feb. 16, 2012 /PRNewswire via COMTEX/ -- Receptos Inc. announced today the publication of key results relating to its expertise in S1P1 biology and structure-based drug discovery for high-value G-protein-coupled receptor (GPCR) targets in Science.

Tetraphase Pharmaceuticals, Inc.

BARDA Awards Contract Worth up to $67 Million for the Development of a Novel Tetraphase Antibiotic

BARDA Awards Contract Worth up to $67 Million for the Development of a Novel Tetraphase Antibiotic

February 16, 2012

WATERTOWN, Mass., Feb 16, 2012 (BUSINESS WIRE) -- Tetraphase Pharmaceuticals, Inc., a clinical-stage life science company developing a portfolio of potent new antibiotics designed to be effective against dangerous, drug-resistant bacteria, including multidrug-resistant (MDR) gram-negative pathogens, today announced that the Biomedical Advanced Research and Development Authority (BARDA) has awarded a contract worth up to $67 million for the development of TP-434, a potent new antibiotic effective against multidrug-resistant gram-negative pathogens and the lead product

Quanterix to Collaborate With the Forsyth Institute and Beth Israel Deaconess Medical Center to Develop Tuberculosis Test

Quanterix to Collaborate With the Forsyth Institute and Beth Israel Deaconess Medical Center to Develop Tuberculosis Test

February 9, 2012

CAMBRIDGE, MA – February 9, 2012 – Quanterix Corporation, a company enabling a new generation of molecular diagnostic tests based on its revolutionary Single Molecule Array (SiMoA™) technology, announced today that it will apply its cutting-edge technology towards the development of an improved test to aid in the diagnosis of active tuberculosis (TB).

BG Medicine, Inc.

BG Medicine, Inc. Appoints Brian S. Posner to its Board of Directors

BG Medicine, Inc. Appoints Brian S. Posner to its Board of Directors

February 13, 2012

WALTHAM, Mass., February 13, 2012 (GLOBE NEWSWIRE) -- BG Medicine, Inc. (Nasdaq:BGMD), a company focused on the development and commercialization of novel, biomarker-based diagnostics, announced the appointment of  Brian S. Posner to its Board of Directors. Mr.